As of May 22
| -0.05 / -0.31%|
The 4 analysts offering 12-month price forecasts for Trinity Biotech PLC have a median target of 26.50, with a high estimate of 30.00 and a low estimate of 21.00. The median estimate represents a +64.09% increase from the last price of 16.15.
The current consensus among 5 polled investment analysts is to Buy stock in Trinity Biotech PLC. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.